NDAORALPOWDER
Approved
Jul 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
3/8 — Basic
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SEPHIENCE (sepiapterin) is an oral powder formulation approved by the FDA on July 28, 2025, representing a novel therapeutic approach from PTC Therapeutics. The specific indication and mechanism of action are not disclosed in available data, but the product is currently in launch phase. Sepiapterin is a cofactor precursor expected to address rare metabolic or neurological conditions.
Growth15.7 years to LOE
Launch-phase product with minimal current market penetration signals opportunity for early-stage team building and market development roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Study of Sepiapterin in Participants With Phenylketonuria (PKU)
Started Mar 2024
56 enrolled
Phenylketonuria
Career Relevance
SEPHIENCE represents a launch-stage opportunity with 15 linked positions spanning directorial, MSL, and scientific roles across medical affairs and commercial teams. Early-career professionals join a rare disease portfolio with significant long-term patent protection and opportunity to build market presence in an uncompetitive space.
Director
Worked on SEPHIENCE at PTC Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.